Innoviva, Inc. (INVA) Stock Analysis
A live, multi-source view of Innoviva, Inc. (INVA): real-time price, technical indicators, Wall Street analyst consensus, recent news sentiment and social buzz — aggregated into one place so you can size up the stock at a glance.
About Innoviva, Inc.
Innoviva, Inc. operates as a biopharmaceutical company in the United States and internationally. Its royalty portfolio includes RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol, and an inhaled corticosteroid, and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, and ABA, VI. The company also markets GIAPREZA for increasing blood pressure in adults with septic or other distributive shock; XACDURO, a co-packaged for intravenous use for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia caused by Acinetobacter; XERAVA for the treatment of complicated intra-abdominal infections in adults; ZEVTERA an advanced-generation cephalosporin antibiotic for the treatment of staphylococcus aureus bacteremia, as well as with right-sided endocarditis, acute bacterial skin and skin structure infections, and community-acquired bacterial pneumonia; NUZOLVENCE for the treatment of uncomplicated urogenital gonorrhea in adults and adolescents.
Sector: Healthcare · Industry: Biotechnology · United States · 159 employees · inva.com
Key statistics · as of 2026-09-05
As of 2026-09-05, Innoviva, Inc. (INVA) had a market capitalization of $1.54B, a trailing P/E of 4.9 (forward 9.7) and a beta of 0.33; the shares traded in a 52-week range of $16.52 – $25.15 (4.3% over the year).
- Market cap
- $1.54B
- Enterprise value
- $1.29B
- Trailing P/E
- 4.9
- Forward P/E
- 9.7
- PEG ratio
- 0.26
- Price / book
- 1.26
- EPS (trailing)
- $4.31
- EPS (forward)
- $2.21
- Payout ratio
- 0.0%
- Ex-dividend date
- 2015-09-08
- 52-week range
- $16.52 – $25.15
- 52-week change
- 4.3%
- Beta
- 0.33
- Average volume
- 759,117
- Shares outstanding
- 72.2M
- Short % of float
- 12.90%
- Profit margin
- 81.2%
Fundamental figures are recorded once every few days, dated above; they are not live and can differ from the interactive tiles.
Last universe scan · 2026-09-11
In RapidTradeView’s 2026-09-11 scan of the US universe, Innoviva, Inc. (INVA) last closed at $20.62 (the last completed close before that scan).
Technicals at the scan: RSI 40 (neutral territory), price -2.3% versus its 20-day average, 20-day versus 50-day average spread -1.1%, MACD histogram 0.01.
Sentiment inputs: StockTwits 100% bullish; analyst consensus score 62/100.
Next scheduled company event: in 54 days from the scan date.
Scan values are recorded once per trading day and are not live quotes; the interactive tiles above update in real time.
Smart Money · last 90 days
RapidTradeView has recorded no Congress or insider filing for INVA in the last 90 days. Coverage of House, Senate and SEC Form 4 filings began in July 2026, and insider sells are tracked for universe tickers only, so this is our record, not a guarantee that nothing was filed. Who is trading what
RapidTradeView pick record
INVA has not appeared in the daily picks yet. Full scoreboard
What this page covers
RapidTradeView pulls Innoviva, Inc. (INVA) data from multiple independent sources and combines it into a single dashboard. Below the summary you’ll find live, interactive tiles for each of the following:
- Price & chart — real-time quote with pre/post-market moves and a line or candlestick chart.
- Technical indicators — RSI, MACD, moving averages, Bollinger Bands, volume and support/resistance, distilled into one overall signal.
- Analyst consensus — the buy/hold/sell breakdown and price targets published by Wall Street analysts.
- News sentiment — recent headlines, each scored for tone so the prevailing narrative is obvious.
- Earnings — current EPS, year-over-year change and the next scheduled earnings date.
- Social buzz — Reddit mention volume and StockTwits sentiment for the retail-trader angle.
How to read the signals
No single indicator tells the whole story. A bullish technical reading paired with a cautious analyst consensus, or strong social buzz against weak earnings, is exactly the kind of tension this view is built to surface. RapidTradeView’s signals are generated by deterministic, statistical models — they describe what the data is doing, they are not personalised recommendations to buy or sell INVA.
Disclaimer: RapidTradeView is an educational sentiment-aggregation tool, not a licensed financial adviser, broker, or dealer. Nothing here is financial, investment, tax, or legal advice. Markets are risky and you can lose money. Always do your own research and consult a qualified professional before making any investment decision.